126 related articles for article (PubMed ID: 37747394)
1. A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy.
Wang K; Tseng CY; Li Z; White C; Wang B; Levine BL; Fesnak AD
Cytotherapy; 2023 Dec; 25(12):1370-1379. PubMed ID: 37747394
[TBL] [Abstract][Full Text] [Related]
2. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
3. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
4. Capacity planning in a decentralized autologous cell therapy manufacturing network for low-cost resilience.
Li J; White CC
Flex Serv Manuf J; 2023; 35(2):295-319. PubMed ID: 36373023
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals.
Ortiz de Landazuri I; Egri N; Muñoz-Sánchez G; Ortiz-Maldonado V; Bolaño V; Guijarro C; Pascal M; Juan M
Front Immunol; 2020; 11():573179. PubMed ID: 33178200
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
7. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
Myles L; Church TD
Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
[TBL] [Abstract][Full Text] [Related]
8. Development of CAR-T cell therapy for B-ALL using a point-of-care approach.
de Macedo Abdo L; Barros LRC; Saldanha Viegas M; Vieira Codeço Marques L; de Sousa Ferreira P; Chicaybam L; Bonamino MH
Oncoimmunology; 2020; 9(1):1752592. PubMed ID: 32363126
[TBL] [Abstract][Full Text] [Related]
9. Competitive advantage, relationship, and benefit: Primary and secondary influencing factors of supply chain collaboration in China's advanced manufacturing industry.
Liu H; Lin L; Cheng Y; Chen X; Ren J
PLoS One; 2023; 18(6):e0285247. PubMed ID: 37279253
[TBL] [Abstract][Full Text] [Related]
10. "After viral load testing, I get my results so I get to know which path my life is taking me": qualitative insights on routine centralized and point-of-care viral load testing in western Kenya from the Opt4Kids and Opt4Mamas studies.
Qian SRW; Hassan SA; Scallon AJ; Oyaro P; Brown E; Wagude J; Mukui I; Kinywa E; Oluoch F; Odhiambo F; Oyaro B; Kingwara L; Yongo N; Karauki E; Gao J; Otieno L; John-Stewart GC; Abuogi LL; Patel RC
BMC Health Serv Res; 2022 Dec; 22(1):1540. PubMed ID: 36528677
[TBL] [Abstract][Full Text] [Related]
11. Putting a price tag on novel autologous cellular therapies.
Abou-El-Enein M; Bauer G; Medcalf N; Volk HD; Reinke P
Cytotherapy; 2016 Aug; 18(8):1056-1061. PubMed ID: 27288308
[TBL] [Abstract][Full Text] [Related]
12. Advancing autologous CAR T-cell therapy through real-time patient health data integration: a simulation-based approach.
Tseng CY; Wang K; Lin LH; Zhang C; White CC; Wang B
Cytotherapy; 2024 May; ():. PubMed ID: 38795115
[TBL] [Abstract][Full Text] [Related]
13. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing innovation to drive down cell therapy costs.
Khang M; Suryaprakash S; Kotrappa M; Mulyasasmita W; Topp S; Wu J
Trends Biotechnol; 2023 Oct; 41(10):1216-1219. PubMed ID: 37236813
[TBL] [Abstract][Full Text] [Related]
15. Logistics Service Selection Strategy of Green Manufacturers in Green Low-Carbon Supply Chain.
Yuan X; Sheng W; Wang M; Zhang D
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834049
[TBL] [Abstract][Full Text] [Related]
16. Autologous CAR T-cell therapies supply chain: challenges and opportunities?
Papathanasiou MM; Stamatis C; Lakelin M; Farid S; Titchener-Hooker N; Shah N
Cancer Gene Ther; 2020 Nov; 27(10-11):799-809. PubMed ID: 31932694
[TBL] [Abstract][Full Text] [Related]
17. Expanding access to CAR T cell therapies through local manufacturing.
Elsallab M; Maus MV
Nat Biotechnol; 2023 Dec; 41(12):1698-1708. PubMed ID: 37884746
[TBL] [Abstract][Full Text] [Related]
18. Supply Chain Decision Analysis of Community E-Commerce Platform under Different Power Structures: Considering the Influence of Value Cocreation.
Liu Z; Li Y
Comput Intell Neurosci; 2021; 2021():2522245. PubMed ID: 34887913
[TBL] [Abstract][Full Text] [Related]
19. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(12):1-114. PubMed ID: 23074516
[TBL] [Abstract][Full Text] [Related]
20. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
